Advances in recurrent endometrial cancer: adavosertib, a WEE1 inhibitor
1 Views
administrator
07/17/23
Ursula Matulonis, MD, Dana-Farber Cancer Institute, Boston, MA evaluates advances in recurrent endometrial cancer treatment and highlights the development of adavosertib, a WEE1 inhibitor that shows over a 30% response rate and represents an additional therapy for patients with recurrent endometrial cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
-
Category
Show more
Facebook Comments
No comments found